Search Results Search Sort by RelevanceMost Recent Case and Commentary Apr 2019 Should a Psychiatrist Prescribe a Nanodrug to Help Parents Monitor a Teen’s Adherence? Constance E. George, MD, MA Ethical stakes include a psychiatrist’s care management responsibilities and burdens borne by family members over the course of the patient’s care. AMA J Ethics. 2019;21(4):E317-323. doi: 10.1001/amajethics.2019.317. Case and Commentary May 2020 How Should Adolescent Health Decision-Making Authority Be Shared? Kimberly Sawyer, MD and Abby R. Rosenberg, MD, MS, MA Shared decision making is complex with patients who are adolescents, whose relational autonomy is still emerging. AMA J Ethics. 2020;22(5):E372-379. doi: 10.1001/amajethics.2020.372. Case and Commentary Aug 2017 Should Clinicians Medicate against Structural Violence? Potential Iatrogenic Risks and the Need for Social Interventions Lauren E. Hock, MD and Niranjan S. Karnik, MD, PhD Risks of off-label medication to treat aggression should be balanced with consequences of not responding to social factors. AMA J Ethics. 2017;19(8):753-761. doi: 10.1001/journalofethics.2017.19.8.ecas2-1708.
Case and Commentary Apr 2019 Should a Psychiatrist Prescribe a Nanodrug to Help Parents Monitor a Teen’s Adherence? Constance E. George, MD, MA Ethical stakes include a psychiatrist’s care management responsibilities and burdens borne by family members over the course of the patient’s care. AMA J Ethics. 2019;21(4):E317-323. doi: 10.1001/amajethics.2019.317.
Case and Commentary May 2020 How Should Adolescent Health Decision-Making Authority Be Shared? Kimberly Sawyer, MD and Abby R. Rosenberg, MD, MS, MA Shared decision making is complex with patients who are adolescents, whose relational autonomy is still emerging. AMA J Ethics. 2020;22(5):E372-379. doi: 10.1001/amajethics.2020.372.
Case and Commentary Aug 2017 Should Clinicians Medicate against Structural Violence? Potential Iatrogenic Risks and the Need for Social Interventions Lauren E. Hock, MD and Niranjan S. Karnik, MD, PhD Risks of off-label medication to treat aggression should be balanced with consequences of not responding to social factors. AMA J Ethics. 2017;19(8):753-761. doi: 10.1001/journalofethics.2017.19.8.ecas2-1708.